Literature DB >> 11734575

Increased plasma apoA-IV level is a marker of abnormal postprandial lipemia: a study in normoponderal and obese subjects.

B Vergès1, B Guerci, V Durlach, C Galland-Jos, J L Paul, L Lagrost, P Gambert.   

Abstract

Plasma apolipoprotein A-IV (apoA-IV) levels are found elevated in hypertriglyceridemic patients. However, the relationship between plasma apoA-IV level and postprandial lipemia is not well known and remains to be elucidated. Thus, our objective was to study the relationship between plasma apoA-IV and postprandial TG after an oral fat load test (OFLT). Plasma apoA-IV was measured at fast and during an OFLT in 16 normotriglyceridemic, normoglucose-tolerant android obese subjects (BMI = 34.6 +/- 2.9 kg/m(2)) and 30 normal weight controls (BMI = 22.2 +/- 2.3 kg/m(2)). In spite of not statistically different fasting plasma TG levels in controls and obese patients, the former group showed an altered TG response after OFLT, featuring increased nonchylomicron TG area under the curve (AUC) compared with controls (516 +/- 138 vs. 426 +/- 119 mmol/l x min, P < 0.05). As compared to controls, obese patients showed increased apoA-IV levels both at fast (138.5 +/- 22.4 vs. 124.0 +/- 22.8 mg/l, P < 0.05) and during the OFLT (apoA-IV AUC: 79,833 +/- 14,281 vs. 68,176 +/- 17,463 mg/l x min, P < 0.05). Among the whole population studied, as among the control and obese subgroups, fasting plasma apoA-IV correlated significantly with AUC of plasma TG (r = 0.60, P < 0.001), AUC of chymomicron TG (r = 0.45, P < 0.01), and AUC of nonchylomicron TG (r = 0.62, P < 0.001). In the multivariate analysis, fasting apoA-IV level constituted an independent and highly significant determinant of AUC of plasma TG, AUC of chymomicron TG, AUC of nonchylomicron TG, and incremental AUC of plasma TG. In conclusion, we show a strong link between fasting apoA-IV and postprandial TG metabolism. Plasma fasting apoA-IV is shown to be a good marker of TG response after an OFLT, providing additional information on post-load TG response in conjunction with other known factors such as fasting TGs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11734575

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  6 in total

Review 1.  ApoA-IV: current and emerging roles in intestinal lipid metabolism, glucose homeostasis, and satiety.

Authors:  Alison B Kohan; Fei Wang; Chun-Min Lo; Min Liu; Patrick Tso
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-01-15       Impact factor: 4.052

2.  Ghrelin and apolipoprotein AIV levels show opposite trends to leptin levels during weight loss in morbidly obese patients.

Authors:  E Pardina; M D López-Tejero; R Llamas; R Catalán; R Galard; H Allende; V Vargas; A Lecube; J M Fort; J A Baena-Fustegueras; J Peinado-Onsurbe
Journal:  Obes Surg       Date:  2009-01-27       Impact factor: 4.129

Review 3.  Apolipoprotein A-IV: a protein intimately involved in metabolism.

Authors:  Fei Wang; Alison B Kohan; Chun-Min Lo; Min Liu; Philip Howles; Patrick Tso
Journal:  J Lipid Res       Date:  2015-02-01       Impact factor: 5.922

4.  Apolipoprotein A-IV, a putative satiety/antiatherogenic factor, rises after gastric bypass.

Authors:  Derek M Culnan; Robert N Cooney; Bruce Stanley; Christopher J Lynch
Journal:  Obesity (Silver Spring)       Date:  2008-10-23       Impact factor: 5.002

5.  Proteomic analysis in type 2 diabetes patients before and after a very low calorie diet reveals potential disease state and intervention specific biomarkers.

Authors:  Maria A Sleddering; Albert J Markvoort; Harish K Dharuri; Skhandhan Jeyakar; Marieke Snel; Peter Juhasz; Moira Lynch; Wade Hines; Xiaohong Li; Ingrid M Jazet; Aram Adourian; Peter A J Hilbers; Johannes W A Smit; Ko Willems Van Dijk
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

6.  Apolipoprotein A4 Defines the Villus-Crypt Border in Duodenal Specimens for Celiac Disease Morphometry.

Authors:  Juha Taavela; Keijo Viiri; Anna Välimäki; Jani Sarin; Kristiina Salonoja; Markku Mäki; Jorma Isola
Journal:  Front Immunol       Date:  2021-07-29       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.